Censo is a leader in the creation of induced Pluripotent Stem Cells (iPSCs) and their transformation to specific cell types for use in drug discovery. Our clients include leading pharmaceutical companies and others involved in drug discovery who recognise that iPSC technology offers a wholly new method for testing drugs with human cells from both specific individuals and large cohorts.
We provide a full spectrum of services from creating iPSCs to drug screening, including:
- Human tissue sample procurement
- iPSC generation
- iPSC genome editing
- Differentiated cell protocol development and industrialisation
- Production of differentiated cells of specific lineages
- Cell based assay development
- Compound screening
We support our clients drug discovery by providing iPSCs and contract research services.
The company was founded in 2016, through the merger of Roslin Cellab and Roslin Cell Sciences, and has facilities in both Edinburgh and Cambridge, UK.
Our long term vision:
As the value of iPSC based compound screening becomes more widely appreciated, researchers will scale up their research to use 100’s of cell lines for “in-vitro clinical trials” and ex-post analysis of responders and non-responders.
Censo has the capacity to generate iPSCs from large cohorts of individuals to meet this growing demand. We will combine this resource with our expertise in the use of iPSC derivatives to play a leading role in the transformation of drug discovery and personalised medicine which will come from the increasing use of iPSC technology.